Kabra Drugs Secures Letter of Intent from Chhattisgarh Government for ₹200 Crore Pharma Manufacturing Project
Kabra Drugs Limited, a pharmaceutical company focused on specialty formulations, injectables, and APIs, has received a Letter of Intent (LOI) from the Government of Chhattisgarh. The LOI is for the establishment of a pharmaceutical manufacturing facility at Nava Raipur Pharma Park in Chhattisgarh.The proposed project includes an investment of approximately ₹200 Crore. This new facility is intended to be established within the strategically located Nava Raipur Pharma Park, which is being developed by the state government. The project is also expected to create around 250 direct and indirect employment opportunities. Kabra Drugs received the LOI on June 12, 2026.
A breakdown of the key elements of the project is provided below:
| Particulars | Details |
|---|---|
| Proposed Investment | Approximately ₹200 Crore |
| Project Location | Nava Raipur Pharma Park, Chhattisgarh |
| Nature of Project | Pharmaceutical Manufacturing Facility and Related Healthcare Manufacturing Activities |
| Employment Generation | Approximately 250 Direct and Indirect Opportunities |
| Authority | Government of Chhattisgarh |
The proposed investment marks a significant step in Kabra Drugs Limited's long term expansion strategy. The company aims to strengthen its operational capabilities, expand production capacity, and capitalize on emerging opportunities within the pharmaceutical and healthcare manufacturing sectors. By establishing the facility at Nava Raipur Pharma Park, Kabra Drugs plans to contribute to regional economic development while supporting its own growth goals.
Nanjappan Aravind, Managing Director of Kabra Drugs Limited, commented on receiving the LOI, stating that it is an important milestone in the company's growth journey. He said that the proposed ₹200 crore investment at Nava Raipur Pharma Park aligns with the company’s vision to expand manufacturing capabilities and strengthen its presence in the pharmaceutical sector. Mr. Aravind added that the project is expected to enhance the operational footprint, create employment opportunities, and support the long term growth strategy, reinforcing the commitment to quality and sustainable value creation for all stakeholders.
Kabra Drugs Limited operates as a research driven pharmaceutical company concentrating on APIs, specialty formulations, and injectables. The Company delivers safe, effective, and globally competitive pharmaceutical solutions, supported by WHO GMP aligned systems and innovation led processes.
Stock Price Movement
Kabra Drugs Ltd settled at ₹23.63 on Friday, with shares climbing 10.27%. Throughout the session, the stock traded within an intraday range between a low of ₹21.75 and a high of ₹25.02.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.